Equities researchers at the Royal Bank of Canada upgraded the rating of uniQure (NASDAQ: QURE) from “sector perform” to “outperform” in a report released on March 27, 2023. The brokerage has set a price target of $35.00 for the biotechnology company’s stock, indicating a potential upside of 145.27% from the previous closing price.
This positive assessment comes alongside varying opinions from other financial analysts. On January 27, Barclays initiated coverage of uniQure with an “equal weight” rating and a target price of $31.00. Following that, on February 10, HC Wainwright reissued a “buy” rating and set a price target of $70.00. Further, on February 23, Wolfe Research began coverage with a “peer perform” rating. In contrast, Chardan Capital reduced its target price from $53.00 to $16.00 while maintaining a “buy” rating, and Weiss Ratings reaffirmed a “sell (d-)” rating on January 21.
Overall, nine investment analysts have rated uniQure with a “buy” rating, while seven have given it a “hold” rating, and one has issued a “sell” rating. According to data from MarketBeat, the stock currently holds a consensus rating of “hold” with an average target price of $40.08.
Financial Performance and Recent Transactions
uniQure recently released its earnings results on March 2, 2023, reporting a loss of ($0.56) per share, which exceeded analysts’ expectations of ($0.93) by $0.37. The company also achieved revenue of $5.57 million for the quarter, surpassing the forecast of $4.84 million. Despite this performance, uniQure reported a negative net margin of 1,236.00% and a negative return on equity of 174.03%. Analysts predict that the company will post an earnings per share of ($3.75) for the current fiscal year.
In related news, Matthew C. Kapusta, CEO of uniQure, sold 14,581 shares on March 4 at an average price of $9.06, totaling approximately $132,104. Following this transaction, he retains 660,658 shares valued at about $5,985,561.48, marking a 2.16% decrease in his holdings. Similarly, insider Jeannette Potts sold 3,412 shares on the same day for a total value of $30,913, resulting in a 2.40% decrease in her position. Over the past 90 days, insiders have sold a total of 81,399 shares valued at approximately $1,527,645, with insiders currently owning 4.79% of the company’s stock.
Institutional Investment and Company Overview
Recent activity from large investors has also been notable. Jefferies Financial Group Inc. acquired a new stake in uniQure in the second quarter worth approximately $29.22 million. State Street Corp increased its stake by 123.8% in the fourth quarter, now holding 3,231,043 shares worth $77.32 million after acquiring an additional 1,787,033 shares. JPMorgan Chase & Co. grew its holdings by 155.3% in the same quarter, now owning 2,934,626 shares valued at $70.23 million. Avoro Capital Advisors LLC also increased its position by 38.4%, holding 6,150,000 shares worth $147.17 million. Currently, institutional investors own 78.83% of uniQure’s stock.
Founded in 1998, uniQure N.V. is a biotechnology company dedicated to developing gene therapies for patients with severe medical conditions. Utilizing its proprietary adeno-associated viral (AAV) vector platform, uniQure focuses on single-dose treatments that target the genetic causes of diseases rather than merely addressing symptoms. Its leading program, Hemgenix® (etranacogene dezaparvovec), has received regulatory approval in both the United States and Europe for treating adult patients with hemophilia B, representing a significant milestone in gene therapy for bleeding disorders. The company’s pipeline includes candidates for various conditions, such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease, highlighting its commitment to addressing rare and debilitating diseases.
